EMA Withdrawn: Vylaer Spiromax (Budesonide;formoterol fumarate dihydrate) — Teva Pharma B.V.

View source ↗

Summary

The EMA has withdrawn Vylaer Spiromax (budesonide/formoterol) from the market in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Vylaer Spiromax (budesonide/formoterol fumarate dihydrate)

Snippet

Status: Withdrawn. Therapeutic area: Pulmonary Disease, Chronic Obstructive;Asthma. MAH: Teva Pharma B.V.. Decision date: 09/01/2017